Cervical Cancer Screening Market will reach US$ 34.92 Billion by 2028, driven by Increased Public Awareness and Technological Breakthroughs in Screening
Global Cervical Cancer Screening Market was US$ 26.7 Billion in 2022 according to Renub Research. Worldwide, cervical cancer is the fourth most diagnosed cancer and the fourth leading cause of cancer death in women. Cervical cancer is driven by persistent disease with a sexually disseminated infection and high-risk types of (HPV) human papillomavirus. Cervical cancer is preventable through screening, HPV vaccination, and treatment of precancerous lesions; it can be effectively treated if diagnosed in its earlier stages. Therefore, the cervical cancer screening test is utilized to find changes in the cervix cells that could lead to cancer. Furthermore, screening includes human papillomavirus (HPV) testing and cervical cytology (also called the Pap test or Pap smear). Most women should have cervical cancer screening regularly.
Global Cervical Cancer Screening Market Size is expected to grow at a CAGR of 4.57% during 2022-2028:
Over the years, the global cervical cancer screening market growth is being driven by the rise in the prevalence of cervical cancer, advancements in cervical cancer screening, and the increase in the female geriatric population. Similarly, active government support, favorable health reimbursement, and rising concern for women’s health also augment the cervical cancer screening industry. As per GLOBOCA, the global burden of cervical cancer is anticipated to increase from 569,847 cases to 642,421 cases by 2025, estimated to fuel the cervical cancer screening market.
COVID-19 Impact on Global Cervical Cancer Screening Industry:
Globally, due to the COVID-19 pandemic, the number of screening tests was reduced. Lockdown has resulted in the devotion of a large number of non-urgent appointments. Things have started to move in the earlier two quarters, but the cancelation screening test numbers have not recovered to pre-COVID-19. During the attempts to deliver cervical cancer screening, preventive measures should be implemented as instructed by the health officers. As per Renub Research Report, The Global Cervical Cancer Test (Screening) Market was US$ 26.7 Billion in 2022.
Country Wise Analysis of Global Cervical Cancer Screening Market:
Based on Countries, the global cervical cancer test (Screening) market includes the United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia. The United States holds a significant market. The growth of the cervical cancer screening market is driven by the increasing number of awareness programs for cervical cancer diagnostic, the high incidence rate of HPV infections, the growing aging female population and rising prevalence rate of cervical cancer, and government initiatives and funding. Breakthrough products and technologies and significant growth in the HPV test market provide new growth opportunities to players in the United States market.
Likewise, despite the declining women population, Japan has the highest demand in the Pap smear test market. The Pap smear test is the most helpful tool for diagnosing HPV in Japanese hospitals and clinics and was the most revenue-generating segment. The Pap smear is a diagnostic procedure that helps Japanese doctors check for cervical cancer in women. It’s utilized to screen for precancerous cells on the cervix before turning into full-blown cancer. Japanese doctors use these screening tests to find and treat irregular changes while there are still no signs of physical damage or disease – this can result in lower rates of death from cervical cancer later down the line.